Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Bullboard Posts
Post by KeySee1on Mar 08, 2018 11:28am
392 Views
Post# 27683398

Somes informations from CEO

Somes informations from CEOMe:
Hi Mr. Adams,
 
first of all thank you for your great job as VPT CEO
I am a shareholder of your company, and I would like to know if VPT is waiting for FDA approval to announce sales of the VMS. Also, is there any problem with FDA approval, seems like the delay is longer than expected. I'm invested since 2 years and really look forward to see some news and hospital buying VPT's product
 
Thank you
Best regards
Patrik

From G.Adams

We are waiting on FDA approval to announce sales in the USA. We did announce new 4 chamber machine at heart centre in Edmonton and we have more to once the machines are installed. I agree it has taken a long time to get traction in a he hospital marketplace as their procurement processes are archaic at best. We have some great sites coming up soon so hang in there.  Sales team in Rurope this week and so we will be getting in depth understanding in major markets UK, Germany,France. 
 
We are still being told cardiac imaging needs to be better and we are the only ones with a breakthrough technology. Everyone wants someone else to go through the learning curve and then tell them how it was. Once we get a few vented using 4C- VMS+ the adoption rate shipyard increase. We are also working to lower the cost of the hardware so we can switch to a SAAS revenue model.  The GST development is moving along very well as the new team under Desmond is experienced and focused. Better cardiac diagnosis and care for all especially children is the goal and we are very close. 
 
Thanks for the support,

George Adams 
Cell: 519.803.6937
Bullboard Posts